Quanta announced that it has received 510(k) clearance from the US Food and Drug Administration (“FDA”) to market its small and simple, high performance hemodialysis system SC+.
by eazee-designstudio
PerkinElmer and Oxford Immunotec Global PLC are pleased to announce they have reached an agreement on terms under which PerkinElmer will acquire Oxford Immunotec.
CARISMA Therapeutics announced today that it has completed its Series B equity financing providing for gross proceeds of $47 million, bringing CARISMA’s total capital raised to nearly $109 million.
CARISMA Therapeutics, announced that Richard Morris has been appointed Chief Financial Officer (CFO).
Adrenomed AG, the vascular integrity company, announced today that its Supervisory Board has appointed Dr. Wolfgang Baiker as Chief Executive Officer (CEO) effective January 1, 2021.
MinervaX, a privately held Danish biotechnology company developing a novel vaccine against Group B Streptococcus (GBS), announced today that it has raised an upsized EUR 47.4 million Series B financing.
Immatics, a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies, announced today that the Company will present Phase I results from their ACTolog® program IMA101 at the 35th Annual SITC Meeting, held virtually from November 9-14, 2020.
The funding round led by Ancora Finance Group and Wellington Partners will bolster Koa Health’s growth ambitions to make mental health treatment more accessible with its wide range of digital solutions.
Nordic digital therapeutics company Sidekick Health has completed a $20 million oversubscribed Series A financing round led by Wellington Partners and Asabys Partners, through its fund SAHII, with participation by existing investors Novator and Frumtak Ventures.
CARISMA Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for the Company's lead product candidate, CT-0508, an anti-human epidermal growth factor receptor 2 (HER2) targeted chimeric antigen receptor macrophage (CAR-M). Under this IND, CARISMA intends to initiate its Phase 1, first-in-human, multi-center study in patients with recurrent or metastatic HER2 overexpressing solid tumors after failure of approved HER2 targeted agents.
